Aura Biosciences, Inc. (NASDAQ:AURA) SVP Sells $10,881.00 in Stock

Aura Biosciences, Inc. (NASDAQ:AURA) SVP Amy Elazzouzi sold 1,404 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $7.75, for a total transaction of $10,881.00. Following the transaction, the senior vice president now directly owns 82,278 shares in the company, valued at approximately $637,654.50. The trade was a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Amy Elazzouzi also recently made the following trade(s):

• On Tuesday, January 21st, Amy Elazzouzi sold 1,001 shares of Aura Biosciences stock. The shares were sold at an average price of $7.67, for a total transaction of $7,677.67.

Aura Biosciences Trading Down 0.3 %

NASDAQ:AURA opened at $7.63 on Friday. The company’s 50-day moving average price is $8.01 and its 200-day moving average price is $8.74. The company has a market cap of $381.12 million, a P/E ratio of -4.41 and a beta of 0.29. Aura Biosciences, Inc. has a twelve month low of $6.63 and a twelve month high of $12.38.

Hedge Funds Weigh In On Aura Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of AURA. SG Americas Securities LLC purchased a new position in shares of Aura Biosciences in the third quarter worth about $169,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Aura Biosciences by 2.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company’s stock worth $1,233,000 after buying an additional 3,612 shares in the last quarter. State Street Corp lifted its stake in shares of Aura Biosciences by 3.7% in the third quarter. State Street Corp now owns 754,803 shares of the company’s stock worth $6,725,000 after buying an additional 26,841 shares in the last quarter. Wellington Management Group LLP acquired a new stake in Aura Biosciences during the third quarter worth about $1,037,000. Finally, Barclays PLC increased its position in Aura Biosciences by 256.5% during the third quarter. Barclays PLC now owns 61,010 shares of the company’s stock worth $544,000 after purchasing an additional 43,897 shares during the last quarter. 96.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on AURA. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price objective on shares of Aura Biosciences in a report on Thursday, November 14th. Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $23.00.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.